Literature DB >> 7135458

Phenytoin metabolism in subjects with long and short plasma half-lives.

A J Glazko, F E Peterson, T Chang, W A Dill, T C Smith, R A Buchanan.   

Abstract

Normal adult men with long and short phenytoin plasma half-lives were given 300-mg oral doses of phenytoin once daily for 15 days. Plasma levels of phenytoin (DPH) and its major metabolite (p-HPPH) were measured during the period of drug administration and for 5 days thereafter. Average steady-state plasma levels of DPH rose to 13.4 micrograms/ml in the long half-life group, compared with 3.6 micrograms/ml in the short half-life group. HPPH levels in the long half-life group were about one half of those observed in the short half-life group. The DPH/HPPH ratios in plasma specimens showed excellent correlation with the plasma half-lives of DPH and average steady-state levels, suggesting that this ratio could provide guidance in the selection of optimum dosage regimens for problem patients.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7135458     DOI: 10.1097/00007691-198208000-00006

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  4 in total

1.  Piperine in food: interference in the pharmacokinetics of phenytoin.

Authors:  T Velpandian; R Jasuja; R K Bhardwaj; J Jaiswal; S K Gupta
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Oct-Dec       Impact factor: 2.441

2.  Lack of pharmacokinetic interaction between nifedipine, sparteine and phenytoin in man.

Authors:  J H Schellens; P A Soons; J H van der Wart; J W Hoevers; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

3.  Lack of effect of erythromycin on the pharmacokinetics of single oral doses of phenytoin.

Authors:  R W Milne; K Coulthard; R L Nation; A C Penna; G Roberts; L N Sansom
Journal:  Br J Clin Pharmacol       Date:  1988-09       Impact factor: 4.335

4.  Inability of ibuprofen to alter single dose phenytoin disposition.

Authors:  K A Bachmann; J I Schwartz; R B Forney; L Jauregui; T J Sullivan
Journal:  Br J Clin Pharmacol       Date:  1986-02       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.